GlassScriptPhysician profile
Solimar A Salud
NPI 1336337435
$3,192.66
in general payments reported to CMS, 2019-2025
30 companies · $666 in 2025
The $666 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $611 · 2020: $86.92 · 2021: $77.98 · 2022: $294 · 2023: $1,020 · 2024: $437 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,122.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $802.21 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $289.80 | 2019-2023 | Jornay Pm |
| Sanofi Pasteur INC. | $232.22 | 2019-2025 | |
| Glaxosmithkline, LLC. | $223.28 | 2019-2025 | Bexsero |
| Genentech USA, INC. | $172.22 | 2019-2022 | |
| Cranial Technologies, INC | $168.19 | 2019-2025 | Doc Band |
| Pfizer INC. | $165.06 | 2022-2025 | |
| Kaleo, INC. | $154.96 | 2019-2023 | Auvi-Q |
| Modernatx, INC. | $147.55 | 2023 | Moderna Covid-19 Vaccine |
| Merck Sharp & Dohme LLC | $125.43 | 2019-2024 | Vaxneuvance, Gardasil, Gardasil 9 |
| Sobi, INC | $93.73 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $84.90 | 2023-2024 | Flumist Quadrivalent |
| Abbott Laboratories | $62.33 | 2025 | Id Now Instrument, Id Now Strep A 2 |
| Neos Therapeutics, LP | $60.80 | 2019-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Alk-Abello, INC | $51.40 | 2025 | Neffy, Grastek, Odactra |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cepheid | $49.81 | 2024 | Genexpert |
| Tris Pharma INC | $47.14 | 2019 | |
| Phadia US INC. | $41.76 | 2019-2022 | |
| Novo Nordisk INC | $24.49 | 2023 | Wegovy |
| Sanofi-Aventis U.S. LLC | $24.47 | 2025 | |
| Verrica Pharmaceuticals INC. | $24.05 | 2025 | Ycanth |
| Kowa Pharmaceuticals America, INC. | $21.42 | 2025 | Zoryve |
| Ars Pharmaceuticals Operations, INC. | $20.23 | 2025 | Neffy |
| Mission Pharmacal Company | $16.51 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $16.20 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.03 | 2019 | |
| Vivus LLC | $14.78 | 2024 | Qsymia |
| Qiagen, LLC | $14.37 | 2022 | |
| Galderma Laboratories, L.P. | $14.36 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $13.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Solimar Salud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.